Oxymatrine induces apoptosis in human cervical cancer cells through guanine nucleotide depletion

Anti-Cancer Drugs

Volumn 25, Issue 2, 2014, Pages 161-173

  Li, Mu ^a   Su, Bao Shan ^a   Chang, Li Hua ^a   Gao, Qing ^a   Chen, Kun Lun ^a   An, Peng ^a   Huang, Chen ^a   Yang, Jun ^a   Li, Zong Fang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

apoptosis; cervical cancer; IMPDH2; oxymatrine; proteome

Indexed keywords

ADENOSINE TRIPHOSPHATE; CISPLATIN; GUANINE NUCLEOTIDE; GUANOSINE TRIPHOSPHATE; OXYMATRINE; PROTEOME; TIAZOFURIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GUANINE NUCLEOTIDES; HUMANS; IMP DEHYDROGENASE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; NEOPLASMS, SQUAMOUS CELL; QUINOLIZINES; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891878070     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000012     Document Type: Article

References (48)

1. Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002; 2:342-350
2. Spitzer M. Screening and management of women and girls with human papillomavirus infection. Gynecol Oncol 2007; 107 (Suppl 1): S14-S18
3. De Ona M, Alvarez-Arguelles ME, Torrents M, Villa L, Rodriguez-Feijoo A, Palacio A, et al. Prevalence, evolution, and features of infection with human papillomavirus: A 15-year longitudinal study of routine screening of a women population in the north of Spain. J Med Virol 2010; 82: 597-604
4. Allan B, Marais DJ, Hoffman M, Shapiro S, Williamson AL. Cervical human papillomavirus (HPV) infection in South African women: implications for HPV screening and vaccine strategies. J Clin Microbiol 2008; 46:740-742
5. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527
6. Karnon J, Peters J, Platt J, Chilcott J, McGoogan E, Brewer N. Liquid-based cytology in cervical screening: An updated rapid and systematic review and economic analysis. Health Technol Assess 2004; 8:1-78
7. US Preventive Services Task Force. Screening for cervical cancer: recommendations and rationale. Am J Nurs 2003; 103:101-102, 105-106, 108-109
8. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002; 26:1389-1399
9. Sivanesaratnam V. The role of chemotherapy in cervical cancer - a review. Singapore Med J 1988; 29:397-401
10. Sun M, Han J, Duan J, Cui Y, Wang T, Zhang W, et al. Novel antitumor activities of Kushen flavonoids in vitro and in vivo. Phytother Res 2007; 21:269-277
11. Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: An emerging field in chemoprevention and chemotherapy research. Pharm Res 2010; 27:1027-1041
12. Kyogoku K, Hatayama K, Komatsu M. Constituents of Chinese crude drug 'Kushen' (the root of Sophora flavescens Ait). Isolation of five new flavonoids and formononetin. Chem Pharm Bull (Tokyo) 1973; 21:2733-2738
13. Han J, Sun M, Cui Y,Wang T, Zhang W, Guo M, et al. Kushen flavonoids induce apoptosis in tumor cells by inhibition of NF-kappaB activation and multiple receptor tyrosine kinase activities. Phytother Res 2007; 21:262-268
14. Sun MY, Zuo J, Duan JF, Han J, Fan SM, Zhang W, et al. Antitumor activities of kushen flavonoids in vivo and in vitro. Zhong Xi Yi Jie He Xue Bao 2008; 6:51-59
15. Zhang Y, Zhang P, Cheng Y. Structural characterization of isoprenylated flavonoids from Kushen by electrospray ionization multistage tandem mass spectrometry. J Mass Spectrom 2008; 43:1421-1431
16. Cao YG, Jing S, Li L, Gao JQ, Shen ZY, Liu Y, et al. Antiarrhythmic effects and ionic mechanisms of oxymatrine from Sophora flavescens. Phytother Res 2010; 24:1844-1849
17. Cui X, Wang Y, Kokudo N, Fang D, Tang W. Traditional Chinese medicine and related active compounds against hepatitis B virus infection. Biosci Trends 2010; 4:39-47
18. Deng ZY, Li J, Jin Y, Chen XL, Lu XW. Effect of oxymatrine on the p38 mitogen-activated protein kinases signalling pathway in rats with CCl4 induced hepatic fibrosis. Chin Med J (Engl) 2009; 122:1449-1454
19. Fan H, Li L, Zhang X, Liu Y, Yang C, Yang Y, et al. Oxymatrine downregulates TLR4, TLR2, MyD88, and NF-kappaB and protects rat brains against focal ischemia. Mediators Inflamm 2009; 2009:704706
20. Song MQ, Zhu JS, Chen JL, Wang L, Da W, Zhu L, et al. Synergistic effect of oxymatrine and angiogenesis inhibitor NM-3 on modulating apoptosis in human gastric cancer cells. World J Gastroenterol 2007; 13:1788-1793
21. Ling Q, Xu X,Wei X,Wang W, Zhou B,Wang B, et al. Oxymatrine induces human pancreatic cancer PANC-1 cells apoptosis via regulating expression of Bcl-2 and IAP families, and releasing of cytochrome c. J Exp Clin Cancer Res 2011; 30:66
22. Zhang Y, Piao B, Hua B, Hou W, Xu W, Qi X, et al. Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells. Med Oncol 2011; 28 (Suppl 1):S99-S107
23. Zou J, Ran ZH, Xu Q, Xiao SD. Experimental study of the killing effects of oxymatrine on human colon cancer cell line SW1116. Chin J Dig Dis 2005; 6:15-20
24. Senda M, Natsumeda Y. Tissue-differential expression of two distinct genes for human IMP dehydrogenase (E.C.1.1.1.205). Life Sci 1994; 54:1917-1926
25. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature 1975; 256:331-333
26. Franchetti P, Cappellacci L, Grifantini M. IMP dehydrogenase as a target of antitumor and antiviral chemotherapy. Farmaco 1996; 51:457-469
27. Chen L, Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel 2007; 10:403-412
28. Vitale M, Zamai L, Falcieri E, Zauli G, Gobbi P, Santi S, et al. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells. Cytometry 1997; 30:61-66
29. Li G, Segu VB, Rabaglia ME, Luo RH, Kowluru A, Metz SA. Prolonged depletion of guanosine triphosphate induces death of insulin-secreting cells by apoptosis. Endocrinology 1998; 139:3752-3762
30. Gu JJ, Gathy K, Santiago L, Chen E, Huang M, Graves LM, et al. Induction of apoptosis in IL-3-dependent hematopoietic cell lines by guanine nucleotide depletion. Blood 2003; 101:4958-4965
31. Penuelas S, Noe V, Ciudad CJ. Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells. FEBS J 2005; 272:696-710
32. Takebe N, Cheng X, Fandy TE, Srivastava RK,Wu S, Shankar S, et al. IMP dehydrogenase inhibitor mycophenolate mofetil induces caspasedependent apoptosis and cell cycle inhibition in multiple myeloma cells. Mol Cancer Ther 2006; 5:457-466
33. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, et al. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene 2005; 24:5888-5896
34. Sun M, Cao H, Sun L, Dong S, Bian Y, Han J, et al. Antitumor activities of kushen: literature review. Evid Based Complement Alternat Med 2012; 2012:11
35. Li LJ, Chen ZQ, Zheng YY, Tang WX, Yu Y. In vitro effects of oxymatrine on human ovarian cancer cell SKOV-3. Shi Yong Zhong Liu Xue Za Zhi 2003; 17:100-101
36. Wang Y, Si WK, Li P, Yao J. Effects of matrine and oxymatrine on the proliferation and apoptosis of A549 cells. Di San Jun Yi Da Xue Xue Bao 2004; 26:778-780
37. Loeffler-Ragg J, Skvortsov S, Sarg B. Gefitinib-responsive EGFR positive colorectal cancers have different proteome profiles from nonresponsive cell lines. Eur J Cancer 2005; 41:2338-2346
38. Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006; 6:3938-3948
39. Takebe N, Cheng X, Wu S, Bauer K, Goloubeva OG, Fenton RG, et al. Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res 2004; 10:8301-8308
40. Zimmermann A, Gu JJ, Spychala J, Mitchell BS. Inosine monophosphate dehydrogenase expression: Transcriptional regulation of the type I and type II genes. Adv Enzyme Regul 1996; 36:75-84
41. Nagai M, Natsumeda Y, Konno Y, Hoffman R, Irino S,Weber G. Selective upregulation of type II inosine 50-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res 1991; 51:3886-3890
42. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenases as drug targets. Ann N Y Acad Sci 1993; 696:88-93
43. Nagai M, Natsumeda Y, Weber G. Proliferation-linked regulation of type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 1992; 52:258-261
44. Ma F, Li XP, Gu JC, Zhang L, Zheng LZ. Protective effects of oxymatrine on adriamycin-induced cardiotoxicity in rabbits and its mechanism. J Shanghai Jiaotong Univ Med Sci 2009; 29:685-688
45. Bateman AR, Harrington KJ, Melcher AA, Vile RG. Cancer gene therapy: developments to 2000. Expert Opin Investig Drugs 2000; 9:2799-2813
46. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55:178-194
47. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6:513-519
48. Pathak S, Sharma H, Sharma C, Jayaram HN, Singh N. Apoptotic signaling induced by tiazofurin-an in vitro study. Gene Ther Mol Biol 2006; 10: 199-206